

BELLICUM PHARMACEUTICALS, INC  
Form 8-K  
March 09, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**March 6, 2015**

**Date of Report (Date of earliest event reported)**

**Bellicum Pharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36783**  
**(Commission**  
  
**File Number)**

**20-1450200**  
**(IRS Employer**  
  
**Identification No.)**

**2130 W. Holcombe Blvd., Ste. 800**

**Houston, TX**  
**(Address of principal executive offices)**

**77030**  
**(Zip Code)**

**Registrant's telephone number, including area code: (832) 384-1100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.**
**(e) Compensatory Arrangements of Named Executive Officers**
*2015 Salary and Target Bonus Information for Certain Executive Officers*

On March 6, 2015, the Compensation Committee (the *Committee*) of the Board of Directors (the *Board*) of Bellicum Pharmaceuticals, Inc. (the *Company*) approved (i) annual base salaries for fiscal year 2015, and (ii) target performance bonuses for fiscal year 2015, for certain of the *Company's* executive officers as set forth below.

The following table sets forth the amounts approved by the *Committee* for certain of the *Company's* executive officers with respect to annual base salaries and target performance bonuses for fiscal year 2015:

| <b>Executive Officer</b>  | <b>2015<br/>Base Salary</b> | <b>2015 Target<br/>Bonus<br/>Percentage</b> |
|---|-----------------------------|---|
| Annemarie Moseley, Ph.D., M.D.<br><i>Chief Operating Officer and<br/>Executive Vice President of Clinical Development</i> | \$ 410,000                  | 40%   |
| Kevin M. Slawin, M.D.<br><i>Chief Technology Officer</i>  | \$ 320,000                  | 35%   |

The base salaries for fiscal year 2015 for Drs. Moseley and Slawin are effective as of January 1, 2015. The target performance bonus amounts for fiscal year 2015 are expressed as a percentage of the corresponding 2015 base salary.

*Equity Award Information for Certain Executive Officers*

On March 6, 2015, the *Committee* approved stock option grants under the *Company's* 2014 Equity Incentive Plan to certain of the *Company's* executive officers, as follows:

| <b>Executive Officer</b>  | <b>Option Awards</b> |
|---|----------------------|
| Annemarie Moseley, Ph.D., M.D.<br><i>Chief Operating Officer and<br/>Executive Vice President of Clinical Development</i> | 100,000              |
| Kevin M. Slawin, M.D.<br><i>Chief Technology Officer</i>  | 60,000               |

The above stock options have an exercise price equal to \$24.48, the closing price of the *Company's* common stock on the grant date, and vest over a four-year period. The stock options entitle the holder, following vesting of the stock option, to acquire the underlying number of shares by paying the exercise price for such shares. The stock options will terminate after 10 years, or earlier if the executive officer ceases to provide services to the *Company*.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Bellicum Pharmaceuticals, Inc.**

Dated: March 6, 2015

By: /s/ Thomas J. Farrell  
Thomas J. Farrell  
President and Chief Executive Officer